Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $63.45 USD
Change Today -1.62 / -2.49%
Volume 739.9K
ABMD On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

abiomed inc (ABMD) Snapshot

Open
$64.77
Previous Close
$65.07
Day High
$65.20
Day Low
$63.20
52 Week High
05/5/15 - $76.90
52 Week Low
05/27/14 - $20.99
Market Cap
2.6B
Average Volume 10 Days
530.7K
EPS TTM
$0.66
Shares Outstanding
41.1M
EX-Date
--
P/E TM
96.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for ABIOMED INC (ABMD)

Related News

No related news articles were found.

abiomed inc (ABMD) Related Businessweek News

No Related Businessweek News Found

abiomed inc (ABMD) Details

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

abiomed inc (ABMD) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $519.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.9K
Chief Operating Officer
Total Annual Compensation: $341.8K
Vice President and General Manager of Global ...
Total Annual Compensation: $297.0K
Senior Vice President of Global Product Opera...
Total Annual Compensation: $284.6K
Compensation as of Fiscal Year 2014.

abiomed inc (ABMD) Key Developments

ABIOMED, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2015; Revises Earnings Guidance for Fiscal Year 2016

ABIOMED, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, the company reported net income of $98,874,000 or $2.24 per diluted share compared to $3,622,000 or $0.09 per diluted share for the same period last year. Income before provision for income taxes was $12,372,000 compared to $3,762,000 for the same period last year. Income from operations was $12,363,000 compared to $3,678,000 for the same period last year. Total revenue was $67,557,000 compared to $50,433,000 for the same period last year. GAAP net income for the quarter and for the year of included an income tax benefit of $86.5 million, primarily due to the release of valuation allowance on most of deferred tax assets. For the full year, the company reported net income of $113,688,000 or $2.65 per diluted share compared to $7,351,000 or $0.18 per diluted share for the same period last year. Income before provision for income taxes was $28,765,000 compared to $8,530,000 for the same period last year. Income from operations was $28,666,000 compared to $8,363,000 for the same period last year. Total revenue was $230,311,000 compared to $183,643,000 for the same period last year. The company is increasing its fiscal year 2016 guidance for total revenue to be in the range of $285 million to $295 million, an increase of 24% to 28% from the prior year. This new range compares to the previous estimated range of $260 million to $270 million. The company is also giving its fiscal year guidance for GAAP operating margin to be in the range of 12% to 16%. For fiscal 2016, the company is increasing expected gross margin rate guidance to be in the range of 83% to 85% from previous expectation of 80% to 82%. The company expects to continue to generate strong cash flows in fiscal 2016.

ABIOMED, Inc. to Report Q4, 2015 Results on May 05, 2015

ABIOMED, Inc. announced that they will report Q4, 2015 results at 8:00 AM, Eastern Daylight on May 05, 2015

ABIOMED, Inc., Q4 2015 Earnings Call, May 05, 2015

ABIOMED, Inc., Q4 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABMD:US $63.45 USD -1.62

ABMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hansen Medical Inc $1.00 USD -0.01
LeMaitre Vascular Inc $10.25 USD +0.04
Stereotaxis Inc $1.86 USD -0.02
Spectranetics Corp/The $24.27 USD -0.20
Thoratec Corp $44.98 USD -0.17
View Industry Companies
 

Industry Analysis

ABMD

Industry Average

Valuation ABMD Industry Range
Price/Earnings 23.9x
Price/Sales 11.3x
Price/Book 9.0x
Price/Cash Flow 22.9x
TEV/Sales 10.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABIOMED INC, please visit www.abiomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.